Box Layout

HTML Layout
Backgroud Images
Backgroud Pattern
  • E-mail :
  • Phone : +86 21 64057580
  • Address : Shanghai China

The worst influenza epidemic in the past decade has hit! The number of hospitalizations in US states has soared

1.HKU said that nasal COVID-19 vaccine and influenza vaccine can be combined into one

he nasal COVID-19 vaccine jointly developed by the University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmaceutical Co., Ltd. was recently approved by the State Drug Administration for emergency use in the mainland. The University of Hong Kong replied to the China News Service reporter’s inquiry that one of the characteristics of this nasal COVID-19 vaccine is that it can be integrated with the influenza vaccine.

2.Waterloo, a 3 billion variety, has created a new “sales crown” of antiemetics!

Nausea and vomiting caused by chemotherapy is one of the most common adverse reactions of cancer patients. Anti emetics and anti nausea drugs are classified as digestive system and metabolic drugs, but they are mainly used in the treatment of vomiting caused by anti-tumor drugs in clinical practice, and play an important role in the field of tumor treatment. According to the data from, the market size of antiemetics and antinausea drugs at the terminals of public medical institutions in China in the first half of 2022 exceeded 2.9 billion yuan. Qilu Pharmaceutical continued to lead the market. Zhengda Tianqing Pharmaceutical Group rushed into TOP2. Hengrui Class 1 new drugs have entered Phase III clinical practice, and a new round of brand shuffling is about to begin.

3.Double anti R&D track is hot! Xinda and other companies have found a market worth more than 200 billion

Recently, the dual anti drug market has been hot: Kangfang Biotech and Summit Therapeutics have reached an overseas licensing transaction of up to 5 billion US dollars for the dual anti drug product AK112, and Wuhan Youzhiyou Biotech, a domestic dual anti drug research and development enterprise, has submitted its IPO listing application… Driven by the favorable market, the dual anti drug also welcomes the research and development boom. At present, there are about 80 kinds of double antibodies in the clinical stage in China. Xinda Bio, Shiyao Holding, Roche, etc. have four or more products under research. Thirteen products of Hengrui Pharmaceutical, such as SHR-1701, Baiji Shenzhou’s Zanidatamab, are in phase III clinical. Double antibodies based on CD47/PD-L1 targets are the most popular, and five products are undergoing clinical trials. CDE has formulated a series of guiding principles for issues that need urgent attention in the clinical research and development of double anti-tumor drugs, To guide enterprises to conduct more scientific clinical research and development of double antibody.

4.The worst influenza epidemic in the past decade has hit! The number of hospitalizations in US states has soared

According to the report on the 5th local time of Axios, the US news website, the worst influenza in more than a decade has hit the medical and health system that has been on the verge of collapse due to the COVID-19 epidemic and respiratory syncytial virus (RSV).

It is reported that the flu has made almost every state at a high or very high level of influenza activity.

According to the US Centers for Disease Control and Prevention (CDC), the number of flu related hospitalizations during Thanksgiving almost doubled from the previous week, the highest since the 2010-2011 flu season. Among them, adults aged 65 and above and children aged 4 and below are most affected, especially if they have potential health problems.

However, about 40% of Americans said they did not plan to vaccinate against influenza in this season, mainly because they were worried about the poor effect or side effects of the vaccine.

Public health experts said that in the past two years, masks and other COVID-19 epidemic prevention measures have largely curbed influenza and blocked its seasonal transmission. However, as people return to their pre epidemic lives, they are also more vulnerable to infection.

Last year, a research team predicted that once personal protective measures were removed, the epidemic situation of children would rebound significantly. The researchers urged the implementation of a strong “follow-up vaccination plan”.

CDC estimates that, so far, at least 8.7 million people have been ill, 78000 have been hospitalized and 4500 have died during the flu season.

According to CNN, the Biden government has promised to provide resources and personnel to help the local health system cope with the surge of influenza, but will not consider declaring a public health emergency.

According to CDC data, between 2009 and 2022, the influenza hospitalization rate of African American adults is nearly 80% higher than that of white adults. However, during the 2021-2022 flu season, less than 43% of African American, Hispanic and Native American adults were vaccinated.

In a letter to the states, the Secretary of the U.S. Department of Health and Human Services, Xavier Bessela, wrote that the federal government can intervene to help the medical system facing pressure, such as allowing hospitals with shortage of staff to enjoy exemption to increase the ability to treat patients, or make them more likely to transfer patients with influenza, COVID-19 or RSV.

JinDun Medical has long-term scientific research cooperation and technology grafting with Chinese universities. With Jiangsu’s rich medical resources, it has long-term trade relations with India, Southeast Asia, South Korea, Japan and other markets. It also provides market and sales services in the whole process from intermediate to finished product API. Utilize the accumulated resources of Yangshi Chemical in fluorine chemistry to provide special chemical customization services for partners. Provide process innovation and impurity research services to target customers.

JinDun Medical insists on creating a team with dreams, making products with dignity, meticulous, rigorous, and go all out to be a trusted partner and friend of customers!One stop solution providers, customized R&D and customized production services for pharmaceutical intermediates and APIs, professional customized pharmaceutical production (CMO) and customized pharmaceutical R&D and production (CDMO) service providers. Jindun will accompany you to spend COVID-19.

  • date


  • location

    Shanghai, China